The case for & against
Bull & Bear analysis
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is an emerging biotechnology firm focused on developing therapeutic options for patients with kidney disease, particularly concerning anemia associated with chronic kidney disease (CKD) and dialysis. The company's lead product, Vafcio, aims to become the standard of care for anemia treatment in dialysis patients, while it is also advancing clinical pipelines for rare kidney diseases. Positioned within the health and pharmaceutical sectors, Akebia operates in a competitive landscape where effective treatment options for CKD and related conditions are in high demand.
Bull says
- ↑Vafcio net product revenue rose 60% YoY to $21.3M in Q2 2026
- ↑Patient enrollment grew 41% QoQ to over 10,500 active users
- ↑Gross margin at ~78.8% in Q2 reflects effective cost management
- ↑Positive VOICE trial data strengthens Vafcio’s efficacy profile
- ↑Targeted commercial push in large practices expands market reach
- ↑Strong liquidity and momentum factors support risk-reward case
Bear says
- ↓Total revenues fell 21% YoY to $49.1M, driven by Arixia declines
- ↓Net loss of $8.9M in Q2 vs. $0.2M profit a year ago
- ↓R&D spending rose to $14.1M, pressuring margins
- ↓Generic competition erodes Arixia pricing and revenue outlook
- ↓Cash balance of $155.5M may tighten if new sales delay
- ↓Weak profitability factors and growth concerns weigh on outlook
Investment themes with AKBA
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q3 2024 · Mgmt. Guidance
Transcript signals
Bull points
- We're building significant momentum as we prepare for U.S. market availability of Vapcio, Vatadustat, expected in January of 25.
- Over and over again, I heard from nephrologists that they're ready for a new choice in anemia management for their dialysis patients, and they want to ensure their patients have access.
- we secured TdapA reimbursement from CMS, and we also received Healthcare Common Procedure Coding System, or HCPCS codes, which allows dialysis organizations to submit for VAPCIA reimbursement in January of 25.
Bear points
- At the end of those two years, we have to lower the price of Vafcio, but now we get to fish in the entire pond, if you will, right?
- we do not know exactly what's going to happen with the and the filers for for Rixia. There's no answers that have been conditionally approved at this point in time.
- Total revenue was $37.4 million in the third quarter of 2024, compared to $42 million in the third quarter of 2023. This consisted of $35.6 million of orexia net product revenue as compared to $40.1 million of orexia net product revenue during the third quarter of 2023. The decrease was primarily due to a reduction in volume, partially offset by price increases and execution of our contracting strategy with third-party payers.